新能源汽车动力系统、医疗器械、精细化工，三领域龙头股今日上市丨打新早知道

Group 1: Company Overview - Jianfa Zhixin is a national high-value medical device distributor, primarily engaged in direct sales and distribution of medical devices, providing centralized operation services for medical consumables to hospitals [1][3] - The company is a subsidiary of Xiamen Jianfa Group, with the Xiamen State-owned Assets Supervision and Administration Commission indirectly holding 51.02% of Jianfa Zhixin's shares [3][4] - In 2024, Jianfa Zhixin's revenue is projected to be divided into three main segments: direct sales (11.03 billion, 61.69%), distribution (6.74 billion, 37.68%), and service (112 million, 0.63%) [3][4] Group 2: Financial Metrics - Jianfa Zhixin's asset-liability ratios from 2022 to 2024 are 87.39%, 87.19%, and 86.45%, indicating a high level of debt [5] - The company's liquidity ratios are relatively low, with current ratios of 1.13, 1.12, and 1.12, and quick ratios of 0.90, 0.86, and 0.81 over the same period [5] Group 3: Market Position and Clients - Jianfa Zhixin serves over 3,300 medical institutions across 31 provinces, providing a wide range of products from various well-known manufacturers [4] - The company is positioned as a leader in the high-value interventional device distribution sector, collaborating with major clients such as Beijing Anzhen Hospital and Jilin University First Hospital [4] Group 4: Joint Power Company Overview - United Power, established in 2016, is a spinoff from the A-share giant Huichuan Technology, focusing on providing power systems for new energy vehicles [5][10] - The company is a leader in the new energy vehicle power system sector, participating in over 20 national standard formulations and key R&D projects [10] Group 5: Financial Metrics and Risks - United Power's accounts receivable from 2022 to 2024 are projected to be 1.85 billion, 3.61 billion, and 5.68 billion, representing 20.37%, 29.38%, and 31.45% of total assets respectively [11] - The company has a significant customer base, including over 40 vehicle manufacturers, with a projected output of over 4.5 million power system products in 2024 [10] Group 6: Jin Hua New Material Overview - Jin Hua New Material specializes in the research, production, and sales of ketoxime series fine chemicals, being a leader in the silane crosslinking agent and hydroxylamine salt sectors [12][14] - The company's silane crosslinking agent products have a domestic market share of 27.85%, 31.60%, and 38.16% from 2022 to 2024 [14][15] Group 7: Financial Metrics and Market Risks - Jin Hua New Material plans to invest 5.07 billion (85.74%) in a high-end coupling agent project, with additional funds allocated for R&D and operational support [14] - The company faces potential risks from market demand fluctuations in downstream industries, particularly in real estate and photovoltaic sectors [16]